GHRS

GH Research PLC is a clinical-stage biopharmaceutical company developing novel therapies for psychiatric and neurological disorders using psychedelic compounds. The company's lead product candidate, GH001, is a proprietary inhalable formulation of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) being investigated for treatment-resistant depression and other mental health conditions. GH Research is conducting Phase 2 clinical trials evaluating the safety, efficacy, and optimal dosing of its psychedelic therapies. The company's inhalation delivery approach aims to provide rapid onset and controlled duration of effect compared to oral or intravenous administration. GH Research is part of the emerging psychedelics-based medicine sector focused on addressing unmet needs in mental health treatment.